DemurisTM is a biotechnology company specialising in the discovery of novel antibiotics and other therapeutic agents.

A spin out from Newcastle University (UK) in 2008, Demuris takes interesting ideas for drug screening opportunities and initiates discovery programmes aiming to develop novel lead compounds. The compounds are accompanied by strong intellectual property packages for partnering with pharmaceutical and biotech companies.

Basic academic research is widely acknowledged as providing many of the initial ideas that seed the drug discovery process; however, the market for the results of basic research is limited. Through its close proximity to a world leading academic research institution, the Institute for Cell and Molecular Biosciences (ICaMB), Demuris provides an opportunity for academic researchers to add commercial value to their discoveries. As well as entering collaborations, Demuris is developing a pipeline of internal discovery programmes and we are actively seeking co-discovery partnerships with industry.

The most advanced programmes lie in the antibacterial arena and are underpinned by basic science emerging from one of the worlds largest groups working on fundamental aspects of bacterial cells, the Centre for Bacterial Cell Biology (CBCB)